Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968785 · ClinicalTrials.gov registry record · NA
Renal Denervation in Patients With Uncontrolled Blood Pressure
A NA study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01968785 is a NA study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT01968785, a NA study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The kidneys are an important regulator of blood pressure. Previous research has shown that disrupting the nerves (denervate) of the kidney may successfully decrease blood pressure. In the past, one technique that was used to treat severe high blood pressure was a surgical procedure to cut these nerves. However, this surgery is no longer commonly performed. Another approach to disrupting these nerves is to use the Beta-Cath 3.5F system to deliver a small amount of radiation to the treatment zone. The Beta-Cath 3.5F System (Novoste) is currently approved in the United States to deliver ion dose therapy to re-narrowings that form in the coronary arteries in the heart. This trial is assessing the safety of treating patients with the Beta-Cath 3.5F System (Novoste) to denervate the nerves around the kidney to help control blood pressure in patients with uncontrolled hypertension. 1. Renal artery brachytherapy with beta-emitting source is safe. 2. Renal artery brachytherapy with beta-emitting source can reduce systolic/diastolic blood pressure via renal denervation mechanism within 6 months post treatment.
Interventions
- RADIATION Radiation Dose 25 Gy
- RADIATION Radiation Dose 50 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968785
The ClinicalTrials.gov registry entry for NCT01968785 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation Dose 25 Gy is the first listed.
NCT01968785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01968785 about?
NCT01968785 is a clinical study titled "Renal Denervation in Patients With Uncontrolled Blood Pressure". The kidneys are an important regulator of blood pressure. Previous research has shown that disrupting the nerves (denervate) of the kidney may successfully decrease blood pressure. In the past, one technique that was used to treat severe high blood pressure was a surgical procedure to cut these nerv...
What is the current status of trial NCT01968785?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2013-08. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01968785?
The interventions under investigation include: Radiation Dose 25 Gy (RADIATION), Radiation Dose 50 Gy (RADIATION).
Who is sponsoring clinical trial NCT01968785?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.